Inhibition of IRF-3 activation by VP35 is critical for the high level of virulence of ebola virus

Journal of Virology

Volumn 82, Issue 6, 2008, Pages 2699-2704

  Hartman, Amy L ^a   Bird, Brian H ^c   Towner, Jonathan S ^a   Antoniadou, Zoi Anna ^b   Zaki, Sherif R ^b   Nichol, Stuart T ^a,d  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON REGULATORY FACTOR 3; VIRULENCE FACTOR; VIRUS PROTEIN;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EBOLA VIRUS; FEMALE; IMMUNOHISTOCHEMISTRY; LIVER; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN; TRANSCRIPTION REGULATION; VIRUS HEMORRHAGIC FEVER; VIRUS RECOMBINANT; VIRUS RESISTANCE; VIRUS VIRULENCE;

ANIMALS; EBOLAVIRUS; FEMALE; INTERFERON REGULATORY FACTOR-3; MICE; MICE, INBRED BALB C; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; VIRAL REGULATORY AND ACCESSORY PROTEINS; VIRULENCE;

EBOLA VIRUS; MUS; ZAIRE EBOLAVIRUS;

EID: 40149109042     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.02344-07     Document Type: Article

References (33)

1. Andrejeva, J., K. S. Childs, D. F. Young, T. S. Carlos, N. Stock, S. Goodbourn, and R. E. Randall. 2004. The V proteins of paramyxoviruses bind the IFN-inducible RNA helicase, mda-5, and inhibit its activation of the IFN-beta promoter. Proc. Natl. Acad. Sci. USA 101:17264-17269.
2. Baize, S., E. M. Leroy, M. C. Georges-Courbot, M. Capron, J. Lansoud-Soukate, P. Debre, S. P. Fisher-Hoch, J. B. McCormick, and A. J. Georges. 1999. Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat. Med. 5:423-426.
3. Basler, C. F., A. Mikulasova, L. Martinez-Sobrido, J. Paragas, E. Muhlberger, M. Bray, H. D. Klenk, P. Palese, and A. Garcia-Sastre. 2003. The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3. J. Virol. 77:7945-7956.
4. Basler, C. F., X. Wang, E. Muhlberger, V. Volchkov, J. Paragas, H. D. Klenk, A. Garcia-Sastre, and P. Palese. 2000. The Ebola virus VP35 protein functions as a type IIFN antagonist. Proc. Natl. Acad. Sci. USA 97:12289-12294.
5. Bray, M., K. Davis, T. Geisbert, C. Schmaljohn, and J. Huggins. 1998. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J. Infect. Dis. 178:651-661.
6. Bray, M., S. Hatfill, L. Hensley, and J. W. Huggins. 2001. Haematological, biochemical and coagulation changes in mice, guinea-pigs and monkeys infected with a mouse-adapted variant of Ebola Zaire virus. J. Comp. Pathol. 125:243-253.
7. Cardenas, W. B., Y. M. Loo, M. Gale, Jr., A. L. Hartman, C. R. Kimberlin, L. Martinez-Sobrido, E. O. Saphire, and C. F. Basler. 2006. Ebola virus VP35 protein binds double-stranded RNA and inhibits alpha/beta interferon production induced by RIG-I signaling. J. Virol. 80:5168-5178.
8. Ebihara, H., A. Takada, D. Kobasa, S. Jones, G. Neumann, S. Theriault, M. Bray, H. Feldmann, and Y. Kawaoka. 2006. Molecular determinants of Ebola virus virulence in mice. PLoS Pathog. 2:e73.
9. Feng, Z., M. Cerveny, Z. Yan, and B. He. 2007. The VP35 protein of Ebola virus inhibits the antiviral effect mediated by double-stranded RNA-dependent protein kinase PKR. J. Virol. 81:182-192.
10. Garcia-Sastre, A., and C. A. Biron. 2006. Type 1 interferons and the virus-host relationship: a lesson in detente. Science 312:879-882.
11. Gupta, M., P. Greer, S. Mahanty, W. J. Shieh, S. R. Zaki, R. Ahmed, and P. E. Rollin. 2005. CD8-mediated protection against Ebola virus infection is perforin dependent. J. Immunol. 174:4198-4202.
12. Gupta, M., S. Mahanty, M. Bray, R. Ahmed, and P. E. Rollin. 2001. Passive transfer of antibodies protects immunocompetent and imunodeficient mice against lethal Ebola virus infection without complete inhibition of viral replication. J. Virol. 75:4649-4654.
13. Gupta, M., S. Mahanty, P. Greer, J. S. Towner, W. J. Shieh, S. R. Zaki, R. Ahmed, and P. E. Rollin. 2004. Persistent infection with Ebola virus under conditions of partial immunity. J. Virol. 78:958-967.
14. Haasnoot, J., W. de Vries, E. J. Geutjes, M. Prins, P. de Haan, and B. Berkhout. 2007. The Ebola virus VP35 protein is a suppressor of RNA silencing. PLoS Pathog. 3:e86.
15. Haller, O., G. Kochs, and F. Weber. 2006. The interferon response circuit: induction and suppression by pathogenic viruses. Virology 344:119-130.
16. Hartman, A. L., J. E. Dover, J. S. Towner, and S. T. Nichol. 2006. Reverse genetic generation of recombinant Zaire Ebola viruses containing disrupted IRF-3 inhibitory domains results in attenuated virus growth in vitro and higher levels of IRF-3 activation without inhibiting viral transcription or replication. J. Virol. 80:6430-6440.
17. Hartman, A. L., J. S. Towner, and S. T. Nichol. 2004. A C-terminal basic amino acid motif of Zaire ebolavirus VP35 is essential for type I interferon antagonism and displays high identity with the RNA-binding domain of another interferon antagonist, the NS1 protein of influenza A virus. Virology 328:177-184.
18. Honda, K., and T. Taniguchi. 2006. IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat. Rev. Immunol. 6:644-658.
19. Khan, A. S., F. K. Tshioko, D. L. Heymann, B. Le Guenno, P. Nabeth, B. Kerstiens, Y. Fleerackers, P. H. Kilmarx, G. R. Rodier, O. Nkuku, P. E. Rollin, A. Sanchez, S. R. Zaki, R. Swanepoel, O. Tomori, S. T. Nichol, C. J. Peters, J. J. Muyembe-Tamfum, and T. G. Ksiazek. 1999. The reemergence of Ebola hemorrhagic fever, Democratic Republic of the Congo, 1995. Commission de Lutte contre les Epidemies a Kikwit. J. Infect. Dis. 179(Suppl. 1):S76-S86.
20. Ksiazek, T. G., P. E. Rollin, A. J. Williams, D. S. Bressler, M. L. Martin, R. Swanepoel, F. J. Burt, P. A. Leman, A. S. Khan, A. K. Rowe, R. Mukunu, A. Sanchez, and C. J. Peters. 1999. Clinical virology of Ebola hemorrhagic fever (EHF): virus, virus antigen, and IgG and IgM antibody findings among EHF patients in Kikwit, Democratic Republic of the Congo, 1995. J. Infect. Dis. 179(Suppl. 1):S177-S187.
21. Ksiazek, T. G., C. P. West, P. E. Rollin, P. B. Jahrling, and C. J. Peters. 1999. ELISA for the detection of antibodies to Ebola viruses. J. Infect. Dis. 179(Suppl. 1):S192-S198.
22. Mahanty, S., M. Gupta, J. Paragas, M. Bray, R. Ahmed, and P. E. Rollin. 2003. Protection from lethal infection is determined by innate immune responses in a mouse model of Ebola virus infection. Virology 312:415-424.
23. Mohamadzadeh, M., L. Chen, and A. L. Schmaljohn. 2007. How Ebola and Marburg viruses battle the immune system. Nat. Rev. Immunol. 7:556-567.
24. Muhlberger, E., M. Weik, V. E. Volchkov, H. D. Klenk, and S. Becker. 1999. Comparison of the transcription and replication strategies of Marburg virus and Ebola virus by using artificial replication systems. J. Virol. 73:2333-2342.
25. Reid, S. P., L. W. Leung, A. L. Hartman, O. Martinez, M. L. Shaw, C. Carbonnelle, V. E. Volchkov, S. T. Nichol, and C. F. Basler. 2006. Ebola virus VP24 binds karyopherin α1 and blocks STAT1 nuclear accumulation. J. Virol. 80:5156-5167.
26. Sanchez, A., T. W. Geisbert, and H. Feldmann. 2006. Filoviridae: Marburg and Ebola viruses, p. 1409-1448. In D. M. Knipe, P. M. Howley, D. E. Griffin, R. A. Lamb, M. A. Martin, B. Roizman, and S. E. Straus (ed.), Fields virology, 5th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
27. Talon, J., C. M. Horvath, R. Polley, C. F. Basler, T. Muster, P. Palese, and A. Garcia-Sastre. 2000. Activation of interferon regulatory factor 3 is inhibited by the influenza A virus NS1 protein. J. Virol. 74:7989-7996.
28. Towner, J. S., J. Paragas, J. E. Dover, M. Gupta, C. S. Goldsmith, J. W. Huggins, and S. T. Nichol. 2005. Generation of eGFP expressing recombinant Zaire ebolavirus for analysis of early pathogenesis events and high-throughput antiviral drug screening. Virology 332:20-27.
29. Towner, J. S., P. E. Rollin, D. G. Bausch, A. Sanchez, S. M. Crary, M. Vincent, W. F. Lee, C. F. Spiropoulou, T. G. Ksiazek, M. Lukwiya, F. Kaducu, R. Downing, and S. T. Nichol. 2004. Rapid diagnosis of Ebola hemorrhagic fever by reverse transcription-PCR in an outbreak setting and assessment of patient viral load as a predictor of outcome. J. Virol. 78:4330-4341.
30. Towner, J. S., T. K. Sealy, T. G. Ksiazek, and S. T. Nichol. 2007. High-throughput molecular detection of hemorrhagic fever virus threats with applications for outbreak settings. J. Infect. Dis. 196(Suppl. 2):S205-S212.
31. Unterstab, G., S. Ludwig, A. Anton, O. Planz, B. Dauber, D. Krappmann, G. Heins, C. Ehrhardt, and T. Wolff. 2005. Viral targeting of the interferon-β-inducing Traf family member-associated NF-κB activator (TANK)-binding kinase-1. Proc. Natl. Acad. Sci. USA 102:13640-13645.
32. U.S. Department of Health and Human Services, U.S. Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. 2007. Biosafety in microbiological and biomedical laboratories, 5th ed. www.cdc.gov/OD/ohs/biosfty/bmbl5/BMBL_5th_edition.pdf.
33. Xiang, Y., R. C. Condit, S. Vijaysri, B. Jacobs, B. R. Williams, and R. H. Silverman. 2002. Blockade of interferon induction and action by the E3L double-stranded RNA binding proteins of vaccinia virus. J. Virol. 76:5251-5259.